LT2641596T - Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders - Google Patents
Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disordersInfo
- Publication number
- LT2641596T LT2641596T LTEP13170128.6T LT13170128T LT2641596T LT 2641596 T LT2641596 T LT 2641596T LT 13170128 T LT13170128 T LT 13170128T LT 2641596 T LT2641596 T LT 2641596T
- Authority
- LT
- Lithuania
- Prior art keywords
- diphenylprop
- derivatives
- treating liver
- liver disorders
- disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/76—Ketones containing a keto group bound to a six-membered aromatic ring
- C07C49/782—Ketones containing a keto group bound to a six-membered aromatic ring polycyclic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09306146 | 2009-11-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT2641596T true LT2641596T (en) | 2018-08-10 |
Family
ID=43587223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEP13170128.6T LT2641596T (en) | 2009-11-26 | 2010-11-26 | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US8772342B2 (en) |
| EP (2) | EP2504005B1 (en) |
| JP (4) | JP5833016B2 (en) |
| KR (2) | KR101865677B1 (en) |
| CN (2) | CN104434891B (en) |
| AU (1) | AU2010323066B2 (en) |
| BR (1) | BR112012012815B8 (en) |
| CA (1) | CA2781451C (en) |
| CY (2) | CY1116548T1 (en) |
| DK (2) | DK2641596T3 (en) |
| EA (1) | EA020849B1 (en) |
| ES (2) | ES2681794T3 (en) |
| HK (1) | HK1175716A1 (en) |
| HU (1) | HUE039731T2 (en) |
| IL (2) | IL219914A (en) |
| LT (1) | LT2641596T (en) |
| MX (1) | MX2012006062A (en) |
| NZ (1) | NZ600439A (en) |
| PL (2) | PL2504005T3 (en) |
| PT (2) | PT2641596T (en) |
| SI (2) | SI2641596T1 (en) |
| TR (1) | TR201810393T4 (en) |
| WO (1) | WO2011064350A1 (en) |
| ZA (1) | ZA201204658B (en) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10722575B2 (en) | 2009-11-26 | 2020-07-28 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
| US9221751B2 (en) | 2009-11-26 | 2015-12-29 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
| PT2641596T (en) * | 2009-11-26 | 2018-07-31 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
| MY191100A (en) | 2011-01-31 | 2022-05-30 | Cadila Healthcare Ltd | Treatment for lipodystrophy |
| US20150352065A1 (en) * | 2013-01-18 | 2015-12-10 | Genfit | Methods of treatment of fibrosis and cancers |
| WO2014174524A1 (en) | 2013-04-22 | 2014-10-30 | Cadila Healthcare Limited | A novel composition for nonalcoholic fatty liver disease (nafld) |
| EP3004053B1 (en) | 2013-05-30 | 2021-03-24 | Cadila Healthcare Limited | A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities |
| TW201513857A (en) | 2013-07-05 | 2015-04-16 | Cadila Healthcare Ltd | Synergistic compositions |
| IN2013MU02470A (en) | 2013-07-25 | 2015-06-26 | Cadila Healthcare Ltd | |
| WO2015033357A2 (en) | 2013-09-06 | 2015-03-12 | Cadila Healthcare Limited | An improved process for the preparation of pyrrole derivatives |
| WO2015189401A1 (en) | 2014-06-13 | 2015-12-17 | Inventiva | Ppar compounds for use in the treatment of fibrotic diseases. |
| PE20180027A1 (en) * | 2015-02-06 | 2018-01-09 | Intercept Pharmaceuticals Inc | PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPY |
| CN108138232B (en) * | 2015-09-14 | 2023-07-18 | 基恩菲特公司 | Methods for diagnosing and assessing non-alcoholic steatohepatitis |
| WO2017064635A2 (en) | 2015-10-14 | 2017-04-20 | Cadila Healthcare Limited | Pyrrole compound, compositions and process for preparation thereof |
| WO2017143038A1 (en) * | 2016-02-16 | 2017-08-24 | Concert Pharmaceuticals, Inc. | Deuterated gft-505 |
| US11331292B2 (en) | 2016-03-31 | 2022-05-17 | Genfit | Methods of treatment of cholestatic diseases |
| WO2017167935A1 (en) * | 2016-03-31 | 2017-10-05 | Genfit | Methods of treatment of cholestatic diseases |
| US12053445B2 (en) | 2016-03-31 | 2024-08-06 | Genfit | Methods of treatment of cholestatic diseases |
| FR3056909B1 (en) * | 2016-09-30 | 2019-04-19 | Nashpharm | COMPOSITION COMPRISING AT LEAST ONE PHARMACEUTICALLY ACCEPTABLE SALT OF SOLUBLE ELAFIBRANOR IN AQUEOUS MEDIA HAVING IMPROVED INTESTINAL ABSORPTION |
| FR3056908B1 (en) * | 2016-09-30 | 2019-04-19 | Nashpharm | METFORMIN AND ELAFIBRANOR SALT HAVING DUAL ACTIVITY FOR THE TREATMENT OF OBESITY ASSOCIATED WITH NON-ALCOHOLIC STEATO-HEPATITIS (NASH) AND HYPERTRIGLYCERIDEMIA |
| JP6840853B2 (en) | 2016-12-09 | 2021-03-10 | カディラ・ヘルスケア・リミテッド | Treatment of primary biliary cholangitis |
| AU2018208913A1 (en) * | 2017-01-22 | 2019-09-12 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of GFT-505 and preparation method and use thereof |
| CN110418641A (en) | 2017-02-24 | 2019-11-05 | 基恩菲特公司 | Pharmaceutical composition for combination treatment |
| US11478440B2 (en) * | 2017-04-18 | 2022-10-25 | Genfit | Combination of Elafibranor or derivatives thereof with an anti-NASH, anti-fibrotic or anti-cholestatic agent |
| CN111148742B (en) | 2017-11-30 | 2021-11-16 | 四川科伦博泰生物医药股份有限公司 | Aromatic compound and pharmaceutical composition and application thereof |
| US12030840B2 (en) | 2018-08-03 | 2024-07-09 | Genfit | Elafibranor salts |
| SG11202103011YA (en) * | 2018-10-11 | 2021-04-29 | Basf As | Aromatic compounds and pharmaceutical uses thereof |
| RU2702003C1 (en) * | 2019-03-18 | 2019-10-03 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургский государственный химико-фармацевтический университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФУ Минздрава России) | Antysteatosis agent |
| WO2020208205A1 (en) * | 2019-04-10 | 2020-10-15 | Genfit | Combination therapy comprising compounds of formula (i) and glp-1 receptor agonists |
| CN110143890B (en) * | 2019-06-12 | 2020-12-22 | 天津科技大学 | Chalcone derivative, synthesis method and application of chalcone derivative in preparation of non-alcoholic steatohepatitis resistant medicine |
| CN110143902B (en) * | 2019-06-12 | 2021-06-04 | 天津科技大学 | Selenium-containing chalcone derivative Compound1, synthesis method and application in non-alcoholic steatohepatitis resisting medicine |
| CN115003653A (en) | 2020-02-10 | 2022-09-02 | 基恩菲特公司 | Polymorphs of elafenol |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04202129A (en) | 1990-11-30 | 1992-07-22 | Terumo Corp | Hepatopathy-treating medicine |
| KR960703901A (en) * | 1993-08-19 | 1996-08-31 | 로즈 암스트롱 | Substituted 2 (5H) furanone, 2 (5H) thiophenone and 2 (5H) pyrrolone derivatives, methods for their preparation and their use as endothelin antagonists (Substituted 2 (5H) Furanone, 2 (5H) Thiophenone and 2 (5H) Pyrrolone Derivatives, Their Preparation and Their Use as Endothelin antagonists) |
| CA2395191A1 (en) | 1999-12-23 | 2001-06-28 | Tedman Ehlers | Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states |
| BR0111889A (en) * | 2000-06-20 | 2003-06-24 | Atherogenics Inc | 1,3-bis- (phenyl-substituted) -2-propen-1-ones and their use to treat vcam-1 mediated disorders |
| KR100567125B1 (en) | 2001-11-01 | 2006-03-31 | 주식회사 안지오랩 | Pharmaceutical composition for inhibiting matrix metalloproteinase activity comprising chalcone or its derivatives |
| FR2841900B1 (en) | 2002-07-08 | 2007-03-02 | Genfit S A | NOVEL SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES |
| FR2841784B1 (en) | 2002-07-08 | 2007-03-02 | COMPOSITION BASED ON SUBSTITUTED 1,3-DIPHENYLPROP-2EN-1-ONE DERIVATIVES, PREPARATION AND USES | |
| FR2857361B1 (en) | 2003-07-08 | 2005-09-09 | Genfit S A | PREPARATION OF 1,3-DIPHENYPROP-2-¼n-1-one DERIVATIVES |
| WO2005073184A1 (en) | 2004-01-08 | 2005-08-11 | Genfit | 1,3-diphenylprop-2-en-1-one derivative compounds, preparation method thereof and uses of same |
| JP4689331B2 (en) | 2005-04-19 | 2011-05-25 | 三菱電機株式会社 | Imaging device |
| FR2902789A1 (en) | 2006-06-21 | 2007-12-28 | Genfit Sa | SUBSTITUTED 1,3-DIPHENYLPROPANE DERIVATIVES, PREPARATIONS AND USES |
| DE102006062264A1 (en) | 2006-12-22 | 2008-06-26 | Joh. Barth & Sohn Gmbh & Co. Kg | Use of xanthohumol for the prevention and / or control of liver diseases |
| PT2641596T (en) | 2009-11-26 | 2018-07-31 | Genfit | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders |
-
2010
- 2010-11-26 PT PT131701286T patent/PT2641596T/en unknown
- 2010-11-26 LT LTEP13170128.6T patent/LT2641596T/en unknown
- 2010-11-26 EA EA201290389A patent/EA020849B1/en not_active IP Right Cessation
- 2010-11-26 ES ES13170128.6T patent/ES2681794T3/en active Active
- 2010-11-26 MX MX2012006062A patent/MX2012006062A/en active IP Right Grant
- 2010-11-26 PL PL10787363T patent/PL2504005T3/en unknown
- 2010-11-26 BR BR112012012815A patent/BR112012012815B8/en active IP Right Grant
- 2010-11-26 NZ NZ600439A patent/NZ600439A/en unknown
- 2010-11-26 EP EP10787363.0A patent/EP2504005B1/en active Active
- 2010-11-26 KR KR1020127016566A patent/KR101865677B1/en active IP Right Grant
- 2010-11-26 AU AU2010323066A patent/AU2010323066B2/en active Active
- 2010-11-26 HU HUE13170128A patent/HUE039731T2/en unknown
- 2010-11-26 CN CN201410458131.4A patent/CN104434891B/en active Active
- 2010-11-26 TR TR2018/10393T patent/TR201810393T4/en unknown
- 2010-11-26 DK DK13170128.6T patent/DK2641596T3/en active
- 2010-11-26 DK DK10787363.0T patent/DK2504005T3/en active
- 2010-11-26 CN CN201080053762.8A patent/CN102647982B/en active Active
- 2010-11-26 PL PL13170128T patent/PL2641596T3/en unknown
- 2010-11-26 US US13/511,170 patent/US8772342B2/en active Active
- 2010-11-26 CA CA2781451A patent/CA2781451C/en active Active
- 2010-11-26 SI SI201031723T patent/SI2641596T1/en unknown
- 2010-11-26 EP EP13170128.6A patent/EP2641596B1/en active Active
- 2010-11-26 PT PT107873630T patent/PT2504005E/en unknown
- 2010-11-26 ES ES10787363.0T patent/ES2441665T3/en active Active
- 2010-11-26 SI SI201030472T patent/SI2504005T1/en unknown
- 2010-11-26 WO PCT/EP2010/068346 patent/WO2011064350A1/en active Application Filing
- 2010-11-26 KR KR1020187008005A patent/KR101962209B1/en active IP Right Grant
- 2010-11-26 JP JP2012540447A patent/JP5833016B2/en active Active
-
2012
- 2012-05-21 IL IL219914A patent/IL219914A/en active IP Right Grant
- 2012-06-22 ZA ZA2012/04658A patent/ZA201204658B/en unknown
-
2013
- 2013-03-13 HK HK13103133.7A patent/HK1175716A1/en unknown
-
2014
- 2014-01-07 CY CY20141100010T patent/CY1116548T1/en unknown
- 2014-05-28 US US14/288,482 patent/US8895619B2/en active Active
-
2015
- 2015-09-21 IL IL241791A patent/IL241791A0/en active IP Right Grant
- 2015-10-28 JP JP2015212306A patent/JP2016074670A/en active Pending
-
2017
- 2017-12-14 JP JP2017239237A patent/JP6594400B2/en active Active
-
2018
- 2018-07-20 CY CY20181100759T patent/CY1120444T1/en unknown
-
2019
- 2019-09-24 JP JP2019173268A patent/JP2020073468A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL241791A0 (en) | Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders | |
| HK1152939A1 (en) | Carboxamide compounds for the treatment of metabolic disorders | |
| LT2229369T (en) | 6,7-dialkoxy-quinazoline derivatives useful for treatment of cancer-related disorders | |
| ZA201107449B (en) | Compounds for the treatment of metabolic disorders | |
| EP2331520A4 (en) | Rosamine derivatives as agents for the treatment of cancer | |
| ZA201107446B (en) | Compounds for the treatment of metabolic disorders | |
| GB0904284D0 (en) | Compounds for the treatment of metabolic disorders | |
| IL210290A0 (en) | Use of pyrimidylaminobenzamide derivatives for the treatment of fibrosis | |
| ZA201204391B (en) | Compounds for the treatment of neurologic disorders | |
| IL209417A0 (en) | 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders | |
| EP2387402A4 (en) | Methods for treating inflammatory disorders using 2,4-pyrimidinediamine compounds | |
| IL207906A0 (en) | Treatment for ocular-related disorders | |
| EP2387565A4 (en) | 2,4-pyrimidinediamine compounds for treatment of inflammatory disorders | |
| PT2278962E (en) | Methods for the treatment of dermatological disorders | |
| GB2476644B (en) | 1,4-Dihydro-1,4-dioxonaphtalene derivatives for the treatment of osteoporosis | |
| EP2240024A4 (en) | Compounds for the treatment of metabolic disorders | |
| GB0904286D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB0904290D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB0904289D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB0904288D0 (en) | Compounds for the treatment of metabolic disorders | |
| GB0724947D0 (en) | Composition for the treatment of psychiatric disorders | |
| EP2240460A4 (en) | Branched diepoxide compounds for the treatment of inflammatory disorders |